Moderna's Stormy Rise 🧐
Moderna (mRNA) stormed the week, closing at $145.04 on Friday with an 8.77% jump. A 130% weekly increase, a 143% monthly gain, and a massive 446% year-on-year performance have made the company one of the most talked-about stocks in the S&P 500. But is this rally a harbinger of the revolution promised by mRNA technology, or a bubble detached from fundamental indicators?
Historic Milestone with mCOMBRIAX
The most significant development that propelled Moderna to this point was the European Commission's marketing approval for mCOMBRIAX (mRNA-1083) on April 21, 2026. This became the world's first mRNA combination vaccine to combine influenza and COVID-19 in a single vaccine. The vaccine, approved for adults aged 50 and over, is valid in EU countries, Iceland, Liechtenstein, and Norway.
A Phase 3 study involving approximately 8,000 adults showed that mRNA-1083 generated a statistically higher immune response against SARS-CoV-2 and three influenza strains (A/H1N1, A/H3N2, B/Victoria) compared to licensed vaccines administered separately. This was Moderna's fourth approved product.
Financial Statement
Moderna's balance sheet shows that this success has not yet been reflected in profit. The P/E ratio is negative (-18.186), and its market value is $57.9 billion. In the last quarter (Q2 2026), revenue was $143 million, while net loss reached $782 million. This reflects the company's research and development expenses and the cost of financing clinical trials.
However, analysts' expectations are optimistic. The average revenue forecast for 2026 is $2.11 billion, and for 2027 it is $2.46 billion. Loss is also expected to narrow: the forecast of -$8.58 per share for 2026 will decrease to -$4.86 in 2027.
Cancer Vaccines and More
mCOMBRIAX is just the beginning. Moderna's pipeline spans a wide range, from cancer vaccines to treatments for rare diseases. One of the most notable developments is the personalized cancer vaccine (mRNA-4157) developed in conjunction with Merck, and vaccines targeting the KRAS variant. Five years of data from a Phase 3 study in melanoma patients have shown promising results.
Also, ahead of the earnings report scheduled for November, the FDA approval process for the company's flu vaccine mRNA-1010 and developments in its CMV (cytomegalovirus) vaccine are being closely watched.
🤔 Expensive or Worth It?
Moderna's price is trading near its highest level in 52 weeks and above its 200-day simple moving average. The 1-year price forecast range from $25 to $170 across 19 analysts. This wide range reflects the uncertainty surrounding the company's future.
Moderna represents the tension between the revolution promised by mRNA technology and current profitability. The commercial success of mCOMBRIAX and data from cancer vaccines will determine the stock's future trajectory.
To avoid missing out on this exciting transformation story and market opportunities, open an investment account now and add mRNA to your watchlist!
DYOR 🔎 NFA ✔️
#GateStockInsightsChallenge $MRNA
Moderna (mRNA) stormed the week, closing at $145.04 on Friday with an 8.77% jump. A 130% weekly increase, a 143% monthly gain, and a massive 446% year-on-year performance have made the company one of the most talked-about stocks in the S&P 500. But is this rally a harbinger of the revolution promised by mRNA technology, or a bubble detached from fundamental indicators?
Historic Milestone with mCOMBRIAX
The most significant development that propelled Moderna to this point was the European Commission's marketing approval for mCOMBRIAX (mRNA-1083) on April 21, 2026. This became the world's first mRNA combination vaccine to combine influenza and COVID-19 in a single vaccine. The vaccine, approved for adults aged 50 and over, is valid in EU countries, Iceland, Liechtenstein, and Norway.
A Phase 3 study involving approximately 8,000 adults showed that mRNA-1083 generated a statistically higher immune response against SARS-CoV-2 and three influenza strains (A/H1N1, A/H3N2, B/Victoria) compared to licensed vaccines administered separately. This was Moderna's fourth approved product.
Financial Statement
Moderna's balance sheet shows that this success has not yet been reflected in profit. The P/E ratio is negative (-18.186), and its market value is $57.9 billion. In the last quarter (Q2 2026), revenue was $143 million, while net loss reached $782 million. This reflects the company's research and development expenses and the cost of financing clinical trials.
However, analysts' expectations are optimistic. The average revenue forecast for 2026 is $2.11 billion, and for 2027 it is $2.46 billion. Loss is also expected to narrow: the forecast of -$8.58 per share for 2026 will decrease to -$4.86 in 2027.
Cancer Vaccines and More
mCOMBRIAX is just the beginning. Moderna's pipeline spans a wide range, from cancer vaccines to treatments for rare diseases. One of the most notable developments is the personalized cancer vaccine (mRNA-4157) developed in conjunction with Merck, and vaccines targeting the KRAS variant. Five years of data from a Phase 3 study in melanoma patients have shown promising results.
Also, ahead of the earnings report scheduled for November, the FDA approval process for the company's flu vaccine mRNA-1010 and developments in its CMV (cytomegalovirus) vaccine are being closely watched.
🤔 Expensive or Worth It?
Moderna's price is trading near its highest level in 52 weeks and above its 200-day simple moving average. The 1-year price forecast range from $25 to $170 across 19 analysts. This wide range reflects the uncertainty surrounding the company's future.
Moderna represents the tension between the revolution promised by mRNA technology and current profitability. The commercial success of mCOMBRIAX and data from cancer vaccines will determine the stock's future trajectory.
To avoid missing out on this exciting transformation story and market opportunities, open an investment account now and add mRNA to your watchlist!
DYOR 🔎 NFA ✔️
#GateStockInsightsChallenge $MRNA










